Sentences with phrase «treating ovarian cancer patients»
In addition to being a member of CRI's Clinical Leadership Committee, Dr. Coukos is currently the lead investigator of a CRI - funded clinical trial that is treating ovarian cancer patients with two immunotherapies — MEDI4736, an anti-PD-L1 checkpoint inhibitor, and motolimod, a TLR8 agonist.
http://cancerresearch.org/
Though smaller in number, some patients with advanced disease and carrying a BRCA mutation may benefit from the same targeted therapy being used today in the clinic to successfully treat some ovarian cancer patients.»
Not exact matches
«For this reason, we decided to combine vitamin C with a PARP inhibitor, a drug type known to cause cancer cell death by blocking the repair of DNA damage, and already approved for treating certain patients with ovarian cancer.»
TRINOVA - 2 is evaluating pegylated liposomal doxorubicin in combination with either placebo or trebananib in previously treated patients with ovarian cancer while TRINOVA - 3, also known as ENGOT - Ov2 and Gynecologic Oncology Group — 3001, is studying the use of trebananib in front - line treatment adding it to carboplatin / paclitaxel.
Dr. Tordjman and her colleagues studied the effect of radioactive iodine treatment on the ovarian reserve of women treated for differentiated thyroid cancer (DTC) by measuring their blood levels of anti-Müllerian hormone (AMH) and following the patients for up to one year after treatment.
A section of a tumor organoid grown from cells derived from a patient with high - grade serous ovarian cancer (left) and a mini-tumor treated with ReACp53, resulting in extensive cancer cell death.
In their research, scientists at Rutgers created animal models that closely resemble the cancerous tumors found in women with ovarian cancer by injecting tumor tissues obtained from gynecological cancer patients treated at the Cancer Institute into laboratorycancer by injecting tumor tissues obtained from gynecological cancer patients treated at the Cancer Institute into laboratorycancer patients treated at the Cancer Institute into laboratoryCancer Institute into laboratory mice.
Recent studies have shown that rucaparib, a PARP inhibitor, effectively treats patients with platinum - sensitive, relapsed, high - grade ovarian cancer harboring a BRCA mutation.
The targeted therapy rucaparib, which has demonstrated robust clinical activity in ovarian cancer patients with a BRCA mutation, also showed promise in previously treated pancreatic cancer patients with the mutation, according to results from a phase II clinical study.
Dr. June: We have protocols that will be treating patients with mesothelioma, pancreatic cancer, and ovarian cancer, targeting a protein called mesothelin.
In that randomized, double - blind, placebo - controlled, phase III trial, 561 patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who were in complete or partial response to platinum - based chemotherapy were treated with either rucaparib 600 mg orally twice daily (372 patients) or to placebo (189 patients).
The LION trial randomized 650 patients with advanced epithelial ovarian cancer and macroscopic complete resection to either systematic pelvic and para-aortic LNE (323 patients in intention - to - treat cohort), or no LNE (324 patients in intention - to - treat cohort).
Cancer Network presents exclusive coverage on ovarian cancer from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, with reports on the latest clinical research changing the way ovarian cancer patients are being managed and trCancer Network presents exclusive coverage on ovarian cancer from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, with reports on the latest clinical research changing the way ovarian cancer patients are being managed and trcancer from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, with reports on the latest clinical research changing the way ovarian cancer patients are being managed and trcancer patients are being managed and treated.
A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.
Olaparib is a PARP inhibitor, which is already used to treat certain ovarian cancer patients and prevents damaged cancer cells from repairing themselves after chemotherapy or radiotherapy.
At UT Southwestern Medical Center, our gynecologic cancer experts have unmatched expertise in treating patients with ovarian cancer.
May 20, 2015 Study adds diabetes drug with anti-cancer effect to ovarian cancer treatment Several recent studies have suggested that metformin, an established drug developed to treat patients with type II diabetes, may provide significant benefits, including increased survival, to patients being treated for advanced cancers.
«Our study suggests a therapeutic benefit for repurposing a well - tolerated inhibitor with limited toxicity to treat a specific group of ovarian cancer patients with high levels of CARM1 expression,» said Sergey Karakashev, Ph.D., first author of the study and a postdoctoral researcher in the Zhang Lab.
Study In 2006 Danish researchers at the University of Copenhagen published in the Scandinavian Journal of Medicine and Science in Sports the results of a study in which they had done experiments with a group of patients being treated for intestinal cancer, breast cancer, ovarian cancer and testicular cancer.
Research shows that hospitals that treat more than 20 ovarian cancer cases a year and surgeons who operate on more than 10 cases a year have significantly better patient outcomes than lower volume hospitals and surgeons, according to the Valley Health System.